Original Source(s)
Related Content
FDA approves hepcidin mimetic for PV
Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.
August 31, 2026
-
3 min
Enterovirus diversity may limit treatment advances
Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.
September 8, 2026
-
4 min
Menopause may be underdocumented in EHRs
Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.
September 14, 2026
-
4 min